What is Post-Marketing Surveillance of Medical Devices in India?  

Getting a medical device approved is only half the job. What happens after the product is in the market is equally important — and often where companies fall short.

That is where Post-Market Surveillance (PMS) comes in. Under the Central Drugs Standard Control Organisation (CDSCO), manufacturers and importers are required to continuously monitor the safety and performance of their devices after approval. Neglecting this obligation is not just a compliance risk — it is a risk to patients.

This guide explains post-market surveillance in India in a clear, practical way — what it involves, who is responsible, and how to build a system that keeps your business audit-ready. 

What is Post-Market Surveillance (PMS)?  

Post-Market Surveillance is the systematic process of monitoring a medical device’s safety and performance after it has been approved and placed on the market. It encompasses the ongoing collection, review, and analysis of real-world data gathered from actual device use.

In practical terms, PMS involves:

• Monitoring device performance in real-world clinical and commercial settings
• Collecting and analysing safety and performance data from multiple sources
• Identifying risks, adverse events, or emerging patterns of concern
• Taking corrective actions when safety signals are detected
• Reporting findings to CDSCO in accordance with regulatory timelines

In simple terms — it ensures your device remains safe after it reaches patients. Approval gives you entry into the market. PMS keeps you there.

Why Post-Market Surveillance Matters  

Many companies treat regulatory approval as the finish line. In reality, it is the starting point of a continuous compliance obligation. PMS matters because:

Clinical trials have limits. Pre-market clinical testing is conducted under controlled conditions with a defined patient population. It cannot capture every scenario, patient profile, or usage environment that a device will encounter once it is commercially available.

Real-world performance differs. How a device performs in a hospital setting, in varied geographic conditions, or across a diverse patient population can differ meaningfully from controlled trial data.

Risks emerge at scale. Adverse events or performance issues that occur at low frequency may only become apparent after a device has been used by thousands of patients across multiple centres.

Regulators require it. CDSCO mandates PMS as a condition of market authorisation. Non-compliance carries significant regulatory and legal consequences — including product recalls, licence suspension, and penalties.

Regulatory Framework Governing PMS in India  

Post-market surveillance in India is governed primarily by the following:

Medical Devices Rules, 2017 The central regulatory framework for medical devices in India. Under these rules, PMS is mandatory for all manufacturers and importers of notified medical devices. The rules specify obligations relating to adverse event reporting, periodic safety updates, and field safety corrective actions.

Drugs and Cosmetics Act, 1940 The overarching legislation under which CDSCO operates. Medical devices regulated under this Act are subject to its provisions relating to safety, quality, and post-market obligations.

Materiovigilance Programme of India (MvPI) Launched by the Indian Pharmacopoeia Commission (IPC) in collaboration with CDSCO, MvPI is India’s national programme for monitoring adverse events associated with medical devices. It provides the reporting infrastructure through which manufacturers, importers, healthcare professionals, and patients can report device-related safety concerns.

Together, these frameworks create a comprehensive regulatory environment in which post-market monitoring is not optional — it is an ongoing legal obligation.

Key Components of a PMS System in India  

1. Complaint Handling System  

A structured and documented complaint handling system is the foundation of any effective PMS programme. It must capture all feedback — from healthcare professionals, patients, distributors, and service teams — and ensure that each complaint is investigated appropriately.

An effective complaint handling system includes:

• A formal mechanism for receiving and recording complaints from all channels
• A defined process for investigating each complaint and identifying root cause
• Documentation of investigation findings and corrective actions taken
• Trend monitoring to identify recurring complaint patterns
• Clear timelines for complaint resolution and closure

Poor or unstructured complaint handling is one of the most common PMS failures — and one of the most significant, since missed complaints can mean missed safety signals.

2. Adverse Event Reporting  

Manufacturers and importers are required to report adverse events — incidents in which a device has or may have caused or contributed to serious injury, illness, or death — to CDSCO within prescribed timelines.

Adverse event reporting is a critical regulatory obligation. Key principles include:

• All serious adverse events must be reported to CDSCO promptly
• Reports must include device identification details, a description of the event, patient information (appropriately anonymised), and an assessment of the causal relationship between the device and the event
• India’s MvPI portal provides the reporting infrastructure for adverse event submission
• Both manufacturers and importers bear responsibility for ensuring adverse events occurring in India are reported

Delayed or incomplete adverse event reporting is a major compliance risk and a frequent trigger for regulatory action.

3. Periodic Safety Update Reports (PSUR)  

PSURs are structured regulatory documents that provide a comprehensive review of a device’s safety and benefit-risk profile over a defined period of post-market experience. In India, PSURs are required for:

• Class C medical devices (moderate-to-high risk)
• Class D medical devices (highest risk)

A PSUR must include:

• A summary of all adverse events and complaints received during the reporting period
• An analysis of safety data collected through PMS activities
• A benefit-risk evaluation based on cumulative post-market evidence
• Details of any field safety corrective actions taken during the period
• An assessment of whether the device’s benefit-risk profile remains acceptable

Failure to submit PSURs — particularly for Class C and D devices — is a common and serious compliance gap. ELT Corporate prepares PSURs that meet CDSCO’s requirements and reflect a rigorous, evidence-based analysis of your device’s post-market safety profile.

4. Field Safety Corrective Actions (FSCA)  

When a device is found to pose a risk to patients or users — whether identified through PMS activities, adverse event reports, or complaint trends — the manufacturer or importer must take appropriate field safety corrective actions. These may include:

• Product recall — withdrawal of a device from the market or from patients already using it
• Safety notices — communication to healthcare professionals or users advising of identified risks and recommended precautions
• Technical corrections — modifications to the device, its labelling, or its instructions for use to mitigate the identified risk
• Field modifications — on-site corrections or adjustments to devices already in clinical use

FSCA must be communicated to CDSCO through a Field Safety Notice and, where relevant, coordinated with the MvPI programme. Timely and transparent FSCAs demonstrate regulatory good faith and are far preferable — in both reputational and regulatory terms — to delayed action following escalation by authorities.

5. Trend Analysis and Signal Detection  

Effective PMS is not limited to responding to individual complaints or adverse events. It requires systematic analysis of accumulated data to detect patterns and emerging signals that may not be apparent from any single report.

Trend analysis involves:

• Regular review of complaint data across product lines and time periods
• Statistical analysis to identify rates of adverse events above baseline expectations
• Monitoring of post-market clinical data, published literature, and registry data
• Comparison of field performance against pre-market clinical trial data
• Escalation processes when trend analysis identifies a potential safety signal

Trend analysis transforms PMS from a reactive compliance activity into a proactive risk management tool.

Who is Responsible for PMS?  

Responsibility for post-market surveillance in India is shared across several parties, depending on their role in the supply chain.

Manufacturers The primary responsibility for establishing and operating a PMS system rests with the manufacturer of the medical device. This includes designing and implementing the complaint handling system, conducting trend analysis, preparing PSURs, and taking corrective actions when safety signals are identified.

Importers Indian importers of foreign-manufactured medical devices bear responsibility for ensuring that the foreign manufacturer’s PMS system meets Indian regulatory requirements. Importers must also report adverse events occurring in India to CDSCO and MvPI — they cannot defer entirely to the foreign manufacturer for events on Indian soil.

Authorised Agents Authorised agents of foreign manufacturers act as the regulatory interface with CDSCO. They play a critical role in communicating PMS data between the foreign manufacturer and Indian authorities and ensuring that reporting obligations are met in a timely manner.

eporting Timelines  

While CDSCO continues to develop and refine its specific PMS reporting timelines, the following general principles apply in practice and align with international standards:

• Serious adverse events resulting in death or serious deterioration in health — immediate reporting, typically within 10 to 15 days of the manufacturer or importer becoming aware of the event
• Non-serious adverse events — included in periodic reports such as PSURs
• Field Safety Corrective Actions — notification to CDSCO before or simultaneously with communication to the market

Delayed reporting — particularly of serious adverse events — is treated as a significant regulatory violation and can result in enforcement action, product suspension, or licence cancellation.

Common PMS Compliance Failures  

Based on regulatory experience across the medical device sector, the following are the most frequently observed PMS failures:

Treating approval as the endpoint. Many companies invest significant resources in obtaining CDSCO approval and then allow their post-market compliance activities to lapse. PMS obligations begin the moment the device enters the market and do not diminish over time.

Unstructured complaint handling. Without a formal, documented complaint system, complaints go unrecorded, investigations are inconsistent, and safety signals are missed. CDSCO expects a robust, auditable complaint management process.

Failure to submit PSURs. Particularly among Class C and D device manufacturers and importers, non-submission of PSURs is a widespread compliance gap — and one that CDSCO is increasingly scrutinising.

Delayed adverse event reporting. Delayed reporting of serious adverse events is among the most serious PMS violations. Regulators expect prompt, transparent communication — not reporting after the matter has been resolved internally.

Absence of trend analysis. Collecting complaint and adverse event data without systematically analysing it for patterns negates much of the value of a PMS system.

Inadequate documentation. Even where PMS activities are being conducted, poor documentation means they cannot be demonstrated during an audit. If it is not documented, it did not happen.

Building an Effective PMS System  

An effective post-market surveillance system is structured, documented, integrated, and continuously active. Key elements include:

Establish a formal complaint handling process with defined roles, investigation procedures, timelines, and documentation standards applicable across all channels through which feedback may be received.

Maintain comprehensive and auditable records of all PMS activities — complaints, adverse events, investigations, corrective actions, trend analyses, and reports — in a manner that supports regulatory inspection.

Train internal teams across quality, regulatory affairs, sales, and customer service functions to recognise and correctly escalate potential adverse events and complaints.

Integrate PMS with your Quality Management System (QMS) — PMS should not operate in isolation. It must be embedded within the broader QMS framework and subject to the same documentation, review, and corrective action processes.

Monitor data continuously — PMS is not a quarterly or annual activity. Data collection, review, and signal detection must be ongoing.

Engage proactively with MvPI — participation in India’s materiovigilance infrastructure demonstrates regulatory good faith and ensures your reporting is aligned with national expectations.

PMS vs Pre-Market Evaluation — Understanding the Difference  

Both are equally important. Pre-market evaluation gets your device approved. Post-market surveillance keeps it on the market — and keeps patients safe.

Strategic Perspective — PMS as a Risk Management Tool  

It is a mistake to view post-market surveillance purely as a compliance obligation to be discharged. Companies that approach PMS strategically — as a genuine risk management and business intelligence tool — realise significant advantages.

Early detection of issues prevents minor problems from escalating into product recalls, regulatory action, or patient harm events. A well-functioning PMS system catches signals early, when corrective action is less costly and less disruptive.

Avoidance of recalls protects both patients and brand reputation. Proactive identification and management of safety signals through PMS is far preferable to a reactive recall initiated by a regulator or triggered by a serious adverse event.

Regulatory trust is built over time through consistent, transparent post-market reporting. Companies with a strong PMS track record are treated differently — and more favourably — by regulatory authorities than those with a history of non-compliance or delayed reporting.

Commercial confidence — customers, hospital procurement teams, and institutional buyers are increasingly scrutinising the post-market compliance posture of device suppliers. A robust PMS system is a credible demonstration of your commitment to device safety.

The Direction of PMS Regulation in India  

Post-market surveillance regulation in India is strengthening. Key trends include:

• Increased enforcement activity by CDSCO with respect to PMS obligations for notified medical devices
• Growing alignment of Indian PMS requirements with international frameworks, including the EU MDR and ISO 13485 standards
• Strengthened operation of the MvPI programme and higher expectations around materiovigilance participation
• Greater scrutiny of PSUR submission compliance, particularly for higher-risk Class C and D devices
• Anticipated expansion of PMS obligations to a broader range of device categories as the notified device list grows

Companies that build robust PMS systems now will be well positioned as regulatory expectations continue to rise.

How ELT Corporate Supports Your PMS Compliance  

ELT Corporate provides comprehensive post-market surveillance support for medical device manufacturers, importers, and authorised agents operating in the Indian market.

PMS System Design and Setup We design and implement structured PMS systems tailored to your device class, organisational structure, and existing quality management framework — covering complaint handling, adverse event reporting, trend analysis, and corrective action processes.

PSUR Preparation We prepare Periodic Safety Update Reports for Class C and D devices that meet CDSCO’s requirements and reflect a rigorous, evidence-based review of your device’s post-market safety profile.

Adverse Event Reporting We manage the preparation and submission of adverse event reports to CDSCO and through the MvPI programme — ensuring timely, accurate, and complete reporting in line with regulatory expectations.

FSCA Management Where safety signals require corrective action, we support the planning, documentation, and communication of Field Safety Corrective Actions — including coordination with CDSCO and preparation of Field Safety Notices.

Regulatory Compliance Audit We conduct internal audits of your existing PMS processes against CDSCO requirements — identifying gaps, recommending corrective actions, and preparing your organisation for regulatory inspection.

Training and Capability Building We deliver targeted training for your regulatory affairs, quality, and commercial teams — building internal PMS capability and ensuring your organisation understands its post-market obligations.

Final Thoughts  

Post-market surveillance in India is about continuous responsibility. Regulatory approval is the beginning of your obligations — not the end of them.

Companies that take PMS seriously protect their patients, protect their products, and protect their position in the market. Those that do not face escalating regulatory risk, reputational damage, and the very real possibility of enforcement action or product recall.

Monitor performance. Report issues on time. Maintain proper documentation. Build a system that works — and works continuously.